Newswise — LA JOLLA, Calif., September 18, 2013 – Sanford-Burnham Medical Research Institute (Sanford-Burnham) today announced that its Board of Trustees has elected Gregory T. Lucier chairman of the Institute’s Board. Lucier is chairman and CEO of Life Technologies and will assume the role of Board chairman on September 18.
“We are very pleased to have Greg join our Board as chairman. As we embark on our strategic vision for the next decade, elements such as drug discovery and precision medicine figure prominently. Greg’s extensive experience in these fields will be a valuable resource to the Institute,” said Kristiina Vuori, M.D., Ph.D., president and interim CEO of Sanford-Burnham.
“Greg has had a transformative impact on the life-science sector in San Diego and globally. Given his deep biomedical experience and significant history on the Sanford-Burnham Board, we welcome the energetic leadership that, once again, he will bring as chairman of the Board of Trustees,” echoed T. Denny Sanford, honorary trustee.
Lucier has served previously on Sanford-Burnham’s Board of Trustees from 2005 until 2011; from 2009 until 2011 he was chairman of the Board. He was also a member of the Institute’s strategic advisory committee in 2012 that helped frame Sanford-Burnham’s strategic visioning for the next decade. His commitment to improving human health by enabling medical research, and his experience with personalized medicine align with the key elements of the Institute’s plan for future growth.
”Greg was a member of the committee that developed the Institute’s 10-year strategic vision, so it is timely and fitting that he returns in a key leadership role,” observed Malin Burnham, honorary trustee.
“I am honored to return as chairman of the Sanford-Burnham Board of Trustees,” said Lucier. “Sanford-Burnham has an impressive track record in medical research and a forward-looking technology infrastructure. This combination distinguishes the Institute and provides a blueprint for the future. I’m excited about the opportunity to contribute to Sanford-Burnham’s growth over the next years and help guide its strategic direction.”
Lucier is credited with overseeing the meteoric rise of a promising small company which grew to become a global biotechnology leader. Invitrogen started as a producer of reagents in 1987 and experienced more than a decade of constant growth. Lucier joined Invitrogen in 2003 as president and CEO and oversaw the acquisition of a number of companies, broadening Invitrogen’s product portfolio and expanding globally. The company merged with Applied Biosystems in 2008 to form Life Technologies, which is now a market leader in many of the fields in which it operates. Prior to that, Lucier served as a senior executive at the General Electric Company. He received a bachelor’s degree in engineering from Pennsylvania State University and an MBA from Harvard Business School. He is also on the boards of CareFusion, Synthetic Genomics, and Rady Children’s Hospital.
Lucier will assume the role of Board chairman from M. Wainwright Fishburn, Jr., who will remain a member of the Board. A complete list of Sanford-Burnham’s Trustees can be found here.
###
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug-discovery and stem-cell technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200 scientists and staff in San Diego (La Jolla), California, and Orlando (Lake Nona), Florida. For more information, visit us at sanfordburnham.org.
RSS